用罗莫苏祖马布治疗渐进性伪质性发育不良症
Nicolò Bisceglia1,2, Emanuela Scarano3, Anna Piazza1,2
1Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria, Bologna 40138, Italy.
JCEM case reports
|September 22, 2025
概括
渐进性伪风湿性发育不良症 (PPD) 是一种罕见的遗传性骨疾病. 骨质疏松症药物罗莫苏祖马布 (Romosozumab) 可能有助于降低低骨密度的PPD患者骨折风险.
科学领域:
- 遗传学和骨生物学 遗传学和骨生物学
- 药理学和治疗学 药理学和治疗学
背景情况:
- 渐进性伪风湿性发育不良症 (PPD) 是一种罕见的遗传疾病,影响骨完整性.
- 后期骨质疏松症的特征是关节硬,骨变形和脆弱,增加由于二次骨质疏松症和骨软弱而导致骨折的风险.
研究的目的:
- 探索romosozumab作为PPD患者抗骨折治疗的潜力.
- 评估romosozumab在降低骨折风险的有效性,在PPD患者具有非常低的骨矿物质密度.
主要方法:
- 一份病例报告详细介绍了在患有PPD的患者中使用罗莫祖马布的情况.
- 序列抗骨折疗法开始用romosozumab对于一个患有PPD和骨矿物质密度非常低的患者.
主要成果:
- 通常用于绝经后骨质疏松症的Romosozumab被视为一种治疗选择.
- 该研究提出了一个案例,罗莫苏祖马布被用于潜在地降低PPD患者骨折风险.
结论:
- 在PPD患者中,罗莫苏祖马布可能是连续抗骨折治疗的可行选择.
- 需要进一步调查,以确定罗莫祖马布在治疗PPD并发症中的作用.
相关概念视频
Rheumatic Heart Disease III: Medical Management
289
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
289
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
Olefin Metathesis Polymerization: Ring-Opening Metathesis Polymerization (ROMP)
3.1K
Ring-opening metathesis polymerization or ROMP involves strained cycloalkenes as starting materials. The mechanism of ROMP proceeds by reacting cycloalkene with Grubbs catalyst to give metallacyclobutane intermediate which undergoes a ring-opening reaction to form new carbene. The new carbene reacts with another molecule of cycloalkene. Repetition of these steps leads to the formation of an unsaturated open-chain polymer product. All these steps are reversible, however, relieving the ring...
3.1K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
465
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
465
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
499
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
499
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
439
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
439


